AAV-based Therapies for All Patients with Rare and Serious Neurological Disorders

Lacerta Therapeutics

Share on facebook
Share on twitter
Share on linkedin

Clinical-stage gene therapy provides cures for the central nervous system and lysosomal storage diseases. The proprietary adeno-associated virus (AAV) vector technology platform develops novel AAV vectors with improved transduction, tissue- or cell subtype-selectivity, and immune escape profiles.

Makes AAV-based therapies available for all patients with rare and serious neurological disorders.